Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

 

  • Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM) CAR-T
  • A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum
  • Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220
  • Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma
  • Phase 1 Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects with Relapsed or Refractory Multiple Myeloma
  • "A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) and previously treated with ruxolitinib."
  • A phase 1/2, multicentre, open-label, study to determine the recommended dose and regimen, and evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments in subjects with relapsed or refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM).
  • Preliminary Efficacy of CC-99282 in Combination with Obinutuzumab in Subjects with
  • "RFP No.: 17-5014"
  • A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of
  • bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma
  • (RRMM) (KarMMa-3)